321 results on '"Seghatchian, Jerard"'
Search Results
2. Spotlights on the trends in performance assessment of qualitative in vitro diagnostic medical devices in transfusion medicine
3. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!
4. Cryopreservation of apheresis platelets treated with riboflavin and UV light
5. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes
6. Blood transfusion in autoimmune rheumatic diseases
7. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron
8. SARS-CoV-2 and cancer: the intriguing and informative cross-talk
9. Platelet and extracellular vesicles in COVID-19 infection and its vaccines
10. Assessment of extracellular vesicles using IFC for application in transfusion medicine
11. Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity
12. An Overview of Current Position on Cell Therapy in Transfusion Science and Medicine: From Fictional Promises to Factual and Perspectives from Red Cell Substitution to Stem Cell Therapy
13. Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!
14. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research
15. In vitro platelet production for transfusion purposes: Where are we now?
16. Spotlight on the current perspectives on applications of human blood cell culture and organoids: Introductory remarks
17. Cell culture – Fact and fiction
18. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
19. When I need you most: frozen red blood cells for transfusion
20. Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview
21. Poor economics - Transforming challenges in transfusion medicine and science into opportunities
22. Platelet-derived bio-products: Classification update, applications, concerns and new perspectives
23. Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward?
24. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)
25. Platelet rich plasma in treatment of musculoskeletal pathologies
26. Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past
27. Optimal use of blood and innovative approaches to stem cells, regenerative medicine and donor recruitment
28. Pathogen inactivation of whole blood and red cell components: An overview of concept, design, developments, criteria of acceptability and storage lesion
29. Blood doping: The flip side of transfusion and transfusion alternatives
30. Anemia treatment of lymphoproliferative malignancies with erypoiesis: An overview of state of the art
31. Massive transfusion: An overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy
32. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates
33. Current debate on pathogen inactivation of platelet concentrates – To use or not to use?
34. Editorial comments: Two clinical viewpoints from Oslo.
35. The relationship of anti-HPA-1a amount to severity of neonatal alloimmune thrombocytopenia – Where does it stand?
36. The six questions of pathogen reduction technology: An overview of current opinions
37. Updates on pathogen inactivation of plasma using Theraflex methylene blue system
38. An overview of unresolved inherent problems associated with red cell transfusion and potential use of artificial oxygen carriers and ECO-RBC: Current status/future trends
39. Monitoring plasma levels of factor Xa inhibitors: how, why and when?
40. Editorial comments: Looking for some innovative diagnostic or developmental research studies that might influence our laboratory and clinical decision-making.
41. Pathogen-reduction systems for blood components: The current position and future trends
42. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends
43. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience
44. International forum – The “6 Pillars” of best practice in apheresis technologies: Introductory remarks
45. Platelet storage lesion: An update on the impact of various leukoreduction processes on the biological response modifiers
46. What’s happening: An overview of potential adverse reactions associated with apheresis technology
47. What’s happening? The expanding role of apheresis platelet support in neonatal alloimmune thrombocytopenia: Current status and future trends
48. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices
49. Red cell storage lesion: The potential impact of storage-induced CD47 decline on immunomodulation and the survival of leucofiltered red cells
50. The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.